secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-070948
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health enters $4.1M GMP manufacturing agreement with Scorpius for Entolimod ARS
--------------------------------------------------------------------------------

- Scorpius BioManufacturing to perform GMP validation for Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS).
- Total estimated investment ~$4.1M comprising ~$2.4M service fees and pass-through costs for consumables, external services.
- Scorpius to perform cell line verification, GMP scale-up, fill/finish, analytical development, process optimization.
- Purpose is to prepare complete CMC package for FDA BLA submission for Entolimod.
- Manufacturing at Scorpius' San Antonio, TX facility; aims for leaner supply chain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/0000950170-25-070948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/tivc-20250509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer